1887

Abstract

The incidence and patient outcomes of Staphylococcus aureus isolates by iclaprim MIC was determined among patients from two phase 3 studies for the treatment of acute bacterial skin and skin structure infections (ABSSSI), REVIVE-1 and -2. Iclaprim MIC90 values were 0.12 µg ml for S. aureus (0.12 µg ml against methicillin-sensitive and 0.25 µg ml against methicillin-resistant S. aureus ). The incidence of culture confirmed S. aureus isolates among patients with ABSSSI with an iclaprim MIC > 8 µg ml was 2.0  % (16/790). The clinical outcomes varied by MICs for early clinical response (63–100  %), end of therapy response (81–100  %) and the test of cure response (75–100  %). For microbiological outcomes of these infections, the end of therapy response was 80–100  % and the test of cure response was 88–100  %.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000989
2019-05-03
2020-01-29
Loading full text...

Full text loading...

References

  1. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases Society of America. Clin Infect Dis 2014;59:e10–e52 [CrossRef]
    [Google Scholar]
  2. Tognetti L, Martinelli C, Berti S, Hercogova J, Lotti T et al. Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment: a collaboration between dermatologists and infectivologists. J Eur Acad Dermatol Venereol 2012;26:931–941
    [Google Scholar]
  3. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother 2007;60:788–794 [CrossRef]
    [Google Scholar]
  4. Sanchez Garcia M, De la Torre MA, Morales G, Pelaez B, Tolon MJ et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010;303:2260–2264
    [Google Scholar]
  5. Mishra NN, Bayer AS, Tran TT, Shamoo Y, Mileykovskaya E et al. Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content. PLoS One 2012;7:e43958 [CrossRef]
    [Google Scholar]
  6. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005;55:283–288 [CrossRef]
    [Google Scholar]
  7. Long SW, Olsen RJ, Mehta SC, Palzkill T, Cernoch PL et al. PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2014;58:6668–6674 [CrossRef]
    [Google Scholar]
  8. Huang DB, File TM Jr, Dryden M, Corey GR, Torres A et al. Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin american and Europe. Diagn Microbiol Infect Dis 2018;90:329–334 [CrossRef]
    [Google Scholar]
  9. Sader HS, Fritsche TR, Jones RN. Potency and bactericidal activity of iclaprim against recent clinical Gram-positive isolates. Antimicrob Agents Chemother 2009;53:2171–2175 [CrossRef]
    [Google Scholar]
  10. Schneider P, Hawser S, Islam K, Iclaprim IK. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 2003;13:4217–4221 [CrossRef]
    [Google Scholar]
  11. Huang DB, Hawser S, Gemmell CG, Sahm DF. In vitro activity of iclaprim against methicillin-resistant Staphylococcus aureus nonsusceptible to daptomycin, linezolid, or vancomycin: a pilot study. Can J Infect Dis Med Microbiol 2017;2017:3948626 [CrossRef]
    [Google Scholar]
  12. Ho JM, Juurlink DN. Considerations when prescribing trimethoprim–sulfamethoxazole. CMAJ 2011;183:1851–1858 [CrossRef]
    [Google Scholar]
  13. Huang DB, O’Riordan W, Overcash JS, Heller B, Amin F et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim vs vancomycin for the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive pathogens: REVIVE-1. Clin Infect Dis 2018;66:1222–1229 [CrossRef]
    [Google Scholar]
  14. Holland TL, O'Riordan W, McManus A, Shin E, Borghei A et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive pathogens (REVIVE-2 study). Antimicrob Agents Chemother 2018;62:e02580–17 [CrossRef]
    [Google Scholar]
  15. Noviello S, Magnet S, Hawser S, Huang DB. In vitro activity of iclaprim against isolates in two phase 3 clinical trials (REVIVE-1 and -2) for acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2019;63: [CrossRef]
    [Google Scholar]
  16. CLSI Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Approved Standard 11th ed M07. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI); 2018; pp19087–1898
    [Google Scholar]
  17. CLSI Performance Standards for Antimicrobial Susceptibility Testing, Informational Suplement Twenty-Eight Edition M100. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI); 2018; pp19087–1898
    [Google Scholar]
  18. Bryant AE, Gomi S, Katahira E, Huang DB, Stevens DL. The effects of iclaprim on exotoxin production in methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. J Med Microbiol 2019;68:456–466 [CrossRef]
    [Google Scholar]
  19. Coelho C, de Lencastre H, Aires-de-Sousa M. Frequent occurrence of trimethoprim-sulfamethoxazole hetero-resistant Staphylococcus aureus isolates in different African countries. Eur J Clin Microbiol Infect Dis 2017;36:1243–1252 [CrossRef]
    [Google Scholar]
  20. Sekiguchi J, Tharavichitkul P, Miyoshi-Akiyama T, Chupia V, Fujino T et al. Cloning and characterization of a novel trimethoprim-resistant dihydrofolate reductase from a nosocomial isolate of Staphylococcus aureus CM.S2 (IMCJ1454). Antimicrob Agents Chemother 2005;49:3948–3951 [CrossRef]
    [Google Scholar]
  21. Nurjadi D, Olalekan AO, Layer F, Shittu AO, Alabi A et al. Emergence of trimethoprim resistance gene dfrG in Staphylococcus aureus causing human infection and colonization in sub-Saharan Africa and its import to Europe. J Antimicrob Chemother 2014;69:2361–2368 [CrossRef]
    [Google Scholar]
  22. Reeve SM, Scocchera EW, G-Dayanadan N, Keshipeddy S, Krucinska J et al. MRSA isolates from United States hospitals carry dfrG and dfrK resistance genes and succumb to propargyl-linked antifolates. Cell Chem Biol 2016;23:1458–1467 [CrossRef]
    [Google Scholar]
  23. Fowler PW, Cole K, Gordon NC, Kearns AM, Llewelyn MJ et al. Robust prediction of resistance to trimethoprim in Staphylococcus aureus. Cell Chem Biol 2018;25:339–349 [CrossRef]
    [Google Scholar]
  24. Gordon NC, Price JR, Cole K, Everitt R, Morgan M et al. Prediction of Staphylococcus aureus antimicrobial resistance by whole-genome sequencing. J Clin Microbiol 2014;52:1182–1191 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000989
Loading
/content/journal/jmm/10.1099/jmm.0.000989
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error